A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).

Authors

null

Lipika Goyal

Massachusetts General Hospital/ Harvard Medical School, Boston, MA

Lipika Goyal , Hui Zheng , Thomas Adam Abrams , Rebecca A. Miksad , Andrea J. Bullock , Jill N. Allen , Matthew B. Yurgelun , Susan Sheehan , Patricia Lynch , Anthony James Afflitto , Caroline Dinicola , Jordan Robert Maurer , Stephanie Reyes , Michelle Knowles , Aralee Galway , Jeffrey W. Clark , Emilie Birnbaum , Anna Khachatryan , Gabriel Dan Duda , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01775501

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 270)

DOI

10.1200/JCO.2018.36.4_suppl.270

Abstract #

270

Poster Bd #

D3

Abstract Disclosures